Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,021Revenue $M548Net Margin (%)-32.2Z-Score6.6
Enterprise Value $M8,795EPS $-1.3Operating Margin %-28.4F-Score3
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-32.2Higher ROA y-yN
Price/Book6.210-y EBITDA Growth Rate %0Quick Ratio6.9Cash flow > EarningsY
Price/Sales15.45-y EBITDA Growth Rate %0Current Ratio8.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-7.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-13.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M146ROI % (ttm)-9.2Gross Margin Increase y-yY

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNRay Dalio 2014-03-31 Buy 0.03%$64.99 - $83.28
($73.66)
$ 61.82-16%New holding, 48400 sh.48,400
BMRNJohn Burbank 2014-03-31 Buy 0.01%$64.99 - $83.28
($73.66)
$ 61.82-16%New holding, 5173 sh.5,173
BMRNJohn Griffin 2013-12-31 Add0.23%$59.3 - $75.09
($67.74)
$ 61.82-9%Add 17.71%2,060,000
BMRNFrank Sands 2013-09-30 Reduce-0.2%$58.64 - $78.388
($66.48)
$ 61.82-7%Reduce -9.49%10,268,812
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 61.82-1%Sold Out0
BMRNFrank Sands 2013-03-31 Add0.24%$49.2 - $62.39
($56.51)
$ 61.829%Add 10.9%10,951,298
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 61.829%Reduce -69.03%40,700
BMRNFrank Sands 2012-12-31 Add1.56%$36.78 - $50.17
($45.59)
$ 61.8236%Add 450.74%9,874,728
BMRNDaniel Loeb 2012-12-31 Sold Out -0.79%$36.78 - $50.17
($45.59)
$ 61.8236%Sold Out0
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 61.8236%Reduce -60.99%131,400
BMRNJohn Griffin 2012-12-31 Reduce-0.28%$36.78 - $50.17
($45.59)
$ 61.8236%Reduce -20.09%1,750,000
BMRNJohn Griffin 2012-09-30 Buy 1.4%$37.23 - $43.29
($39.41)
$ 61.8257%New holding, 2190000 sh.2,190,000
BMRNDaniel Loeb 2012-09-30 Buy 0.79%$37.23 - $43.29
($39.41)
$ 61.8257%New holding, 1000000 sh.1,000,000
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 61.8272%Sold Out0
BMRNRichard Perry 2012-06-30 Sold Out -0.04%$32.53 - $38.87
($36.01)
$ 61.8272%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 61.8287%Add 300%300,000
BMRNRichard Perry 2012-03-31 Buy 0.04%$33.68 - $38.34
($32.99)
$ 61.8287%New holding, 22900 sh.22,900
BMRNGeorge Soros 2011-12-31 Reduce-0.05%$30.07 - $35.38
($32.81)
$ 61.8288%Reduce -57.14%75,000
BMRNGeorge Soros 2011-06-30 Add0.07%$24.93 - $28.455
($26.32)
$ 61.82135%Add 862.36%191,510
BMRNGeorge Soros 2011-03-31 Buy 0.01%$23.46 - $28.29
($25.46)
$ 61.82143%New holding, 19900 sh.19,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMRN Ray Dalio 2014-03-3148,4000.030.03New Buy
BMRN John Burbank 2014-03-315,17300.01New Buy
BMRN PRIMECAP Management 2014-03-318,163,7195.590.63+7.98%
BMRN John Griffin 2014-03-312,060,0001.411.6
BMRN Frank Sands 2014-03-319,737,6656.671.7-4.87%
BMRN Meridian Funds 2013-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SPIEGELMAN DANIEL KEVP, CFO 2014-07-02Sell2,229$64-4.55view
BIENAIME JEAN JACQUESCEO 2014-06-04Sell2,000$61.2-0.18view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2014-06-02Sell377$57.835.64view
BIENAIME JEAN JACQUESCEO 2014-05-22Sell1,000$56.887.4view
BIENAIME JEAN JACQUESCEO 2014-05-21Sell1,545$56.198.72view
LAWLIS V BRYANDirector 2014-05-16Sell1,700$56.877.42view
FUCHS HENRY JEVP, Chief Medical Officer 2014-05-16Sell1,864$56.867.44view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2014-05-16Sell1,004$56.917.34view
FUCHS HENRY JEVP, Chief Medical Officer 2014-05-13Sell1,434$58.234.91view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2014-05-13Sell478$58.185view

Press Releases about BMRN :

    Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 
    BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 11,250 Shares Nov 24 2010 


    More From Other Websites
    BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2014
    4:04 pm Biomarin Pharm sells priority review voucher for $67.5 mln Jul 30 2014
    BioMarin Announces Second Quarter 2014 Financial Results Jul 30 2014
    BioMarin Sells Priority Review Voucher for $67.5 Million Jul 30 2014
    Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Jul 30 2014
    Q2 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close Jul 30 2014
    [video] What's coming in biotech? Jul 23 2014
    Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Jul 23 2014
    Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast... Jul 23 2014
    Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast... Jul 23 2014
    Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Jul 16 2014
    Cramer's Lightning Round - BioMarin Deserves To Be Higher (7/14/14) Jul 15 2014
    'Mad Money' Lightning Round: Wait on Whole Foods Jul 15 2014
    Lightning Round: Whole Foods, Apache & more Jul 14 2014
    BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday,... Jul 09 2014
    BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday,... Jul 09 2014
    BioMarin's Vimizim Gets Canadian Nod Jul 08 2014
    BioMarin Announces Health Canada Approval of VIMIZIM™ (elosulfase alfa) for the Treatment of... Jul 07 2014
    BioMarin Announces Health Canada Approval of VIMIZIM™ (elosulfase alfa) for the Treatment of... Jul 07 2014
    BioMarin Announces Health Canada Approval of VIMIZIM™ (elosulfase alfa) for the Treatment of... Jul 07 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide